|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1993-5-24
|
|
pubmed:abstractText |
To evaluate an intensive therapy regimen of high-dose etoposide and melphalan and autologous bone marrow transplantation (ABMT) in advanced Hodgkin's disease; and to determine possible prognostic factors that predict for long-term disease-free survival (DFS).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
704-11
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8478664-Adolescent,
pubmed-meshheading:8478664-Adult,
pubmed-meshheading:8478664-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8478664-Bone Marrow Transplantation,
pubmed-meshheading:8478664-Combined Modality Therapy,
pubmed-meshheading:8478664-Etoposide,
pubmed-meshheading:8478664-Female,
pubmed-meshheading:8478664-Hodgkin Disease,
pubmed-meshheading:8478664-Humans,
pubmed-meshheading:8478664-Male,
pubmed-meshheading:8478664-Melphalan,
pubmed-meshheading:8478664-Middle Aged,
pubmed-meshheading:8478664-Survival Rate
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant.
|
|
pubmed:affiliation |
University of Toronto Autologous Bone Marrow Transplant Program, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
